Therapeutic intervention with complement and beta-glucan in cancer.
about
Antiinflammatory and immunomodulating properties of fungal metabolitesCharacterization of the human beta -glucan receptor and its alternatively spliced isoformsStructure of the fungal beta-glucan-binding immune receptor dectin-1: implications for functionBeta-glucan enhances complement-mediated hematopoietic recovery after bone marrow injuryCAM and NK CellsMolecular Interactions of β-(1→3)-Glucans with Their Receptorsβ-1,3-Glucan-induced host phospholipase D activation is involved in Aspergillus fumigatus internalization into type II human pneumocyte A549 cellsDectin-1 mediates the biological effects of beta-glucansDectin-1 is a major beta-glucan receptor on macrophagesInhibiting complement regulators in cancer immunotherapy with bispecific mAbs.Enhancement of umbilical cord blood cell hematopoiesis by maitake beta-glucan is mediated by granulocyte colony-stimulating factor production.Protective effects of betaglucin on myocardial tissue during myocardial infarction in rats and dogs.A novel beta-glucan produced by Paenibacillus polymyxa JB115 induces nitric oxide production in RAW264.7 macrophagesCommandeering a biological pathway using aptamer-derived molecular adaptorsThe dectin 1 agonist curdlan regulates osteoclastogenesis by inhibiting nuclear factor of activated T cells cytoplasmic 1 (NFATc1) through Syk kinase.Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complement-mediated attack.Nonopsonic phagocytosis of zymosan and Mycobacterium kansasii by CR3 (CD11b/CD18) involves distinct molecular determinants and is or is not coupled with NADPH oxidase activationEffect of Beta glucan on quality of life in women with breast cancer undergoing chemotherapy: a randomized double-blind placebo-controlled clinical trial.Interaction of two phagocytic host defense systems: Fcγ receptors and complement receptor 3.Brucella β 1,2 cyclic glucan is an activator of human and mouse dendritic cells.GD2-targeted immunotherapy and radioimmunotherapyA phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effectsImmunomodulatory beta-glucan from Lentinus edodes activates mitogen-activated protein kinases and nuclear factor-kappaB in murine RAW 264.7 macrophages.Neuroblastoma: developmental biology, cancer genomics and immunotherapy.β-Glucan from Lentinus edodes inhibits nitric oxide and tumor necrosis factor-α production and phosphorylation of mitogen-activated protein kinases in lipopolysaccharide-stimulated murine RAW 264.7 macrophages.Maitake beta-glucan promotes recovery of leukocytes and myeloid cell function in peripheral blood from paclitaxel hematotoxicityDectin-1 is required for beta-glucan recognition and control of fungal infection.Cellular and molecular effects of yeast probiotics on cancer.Yeast whole glucan particle (WGP) beta-glucan in conjunction with antitumour monoclonal antibodies to treat cancer.Evaluation of electrospun (1,3)-(1,6)-β-D-glucans/biodegradable polymer as artificial skin for full-thickness wound healing.Immunomodulatory activity of acidic polysaccharides isolated from Tanacetum vulgare L.Evaluation of the protective effect of Beta glucan on amikacin ototoxicity using distortion product otoacoustic emission measurements in rats.Evaluation of widely consumed botanicals as immunological adjuvantsDirect and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab.The known immunologically active components of Astragalus account for only a small proportion of the immunological adjuvant activity when combined with conjugate vaccines.Beta-glucans, history, and the present: immunomodulatory aspects and mechanisms of action.Research on stress-induced apoptosis of natural killer cells and the alteration of their killing activity in mouse liver.Beta-glucans as immunostimulant in vertebrates and invertebrates.Potential of the beta-glucans to enhance innate resistance to biological agents.Natural glycans and glycoconjugates as immunomodulating agents.
P2860
Q21284457-034717E8-C787-4567-B12E-0C0447F9994CQ24291717-6F849107-1497-407F-8446-16AC29281F8DQ24648836-AED706D3-239B-4D36-9EF8-684C36AF9462Q24685769-B8552324-2E4F-449C-AC27-E448927D2FF0Q24799074-ADD4E360-2592-4C45-AF41-1E4867EB6606Q26859196-16F30182-79B5-4F30-9F83-C0E9E9AC449EQ28478946-4B32DF51-B7EC-4794-A228-2F3C7B485377Q28509437-E8545B61-5257-45AD-81B9-E95135A69EA4Q28593983-BAEFCEE6-3B73-47DF-A613-8EFE1AEF574DQ33228198-C4F80362-A337-41CA-BB4E-0EAF177610ACQ33263087-99ED67FF-4449-42E3-9DDB-7C7263EAA226Q33552795-7EB6F11C-3D07-4536-86E5-79D22C808A25Q33569033-6ECA52E1-2752-4EB6-9847-23A7B8269CB5Q33783191-652A52BD-1525-4753-8CDF-FA4BE83F5952Q33846556-F39BC808-809C-495A-88FB-74128F38E290Q33896694-497EEEE4-6E3D-4874-9A55-CEF4B2A99D67Q34007906-89F6141D-A92E-417F-AECB-26C998919ED2Q34424432-E0CC655D-5FFA-44B7-8230-70C79753CE8EQ34452468-DE0F153A-76F7-4228-8118-CD511456DFD1Q34481835-3B6582E4-3FFE-48C6-AB20-6669BDF24983Q34625339-1097893C-8F39-4AD0-8D7D-FF5519D160FBQ34954952-8D9C47D4-A8A5-459A-85C6-7DB5F6E702DBQ35213064-A3C3DD9D-DF59-4D76-BFD5-E44EF65BBABFQ35283020-74D3B581-C738-46BE-84DB-AAEC854B881DQ35668752-72D551AB-CE46-466E-8DCB-CCF8B0904974Q35710628-E980F932-6F9D-43D1-BE22-97D854AEDE82Q35837153-1AB9985C-9BAE-4D29-9F81-A15221E82490Q36113199-AAE7B885-D936-4D0A-87D1-9A8A7153CCFCQ36150511-E577B55A-8E28-464A-8973-9C09AD178145Q36352451-29E4B18B-B2E8-4177-81F5-C4BD1191FAABQ36387960-C16A3233-BB34-4BDE-B452-FF7165E81E70Q36704558-8F9B9602-6E0B-4134-8790-FF46AF530166Q36932370-DE8891BB-06DB-4DBD-91AA-860E7D242FC5Q36986787-D7072314-AE16-41BA-B86E-2D13969992E7Q37011520-CDC621A2-2768-4D4B-A0B6-6AAC947F2BA6Q37126054-1CC4CF91-9A90-4D80-AEB9-6F7A0FDD8C89Q37208146-DA206D16-3A09-4492-BA95-768F126A0EB5Q37514264-AA738AE3-F151-4D40-A671-55E222A75C97Q37700561-C7676D1A-6506-4092-A41C-879A8D4A9DE8Q37850328-D505144B-87A6-4AE6-84E8-76E4BFD68363
P2860
Therapeutic intervention with complement and beta-glucan in cancer.
description
1999 nî lūn-bûn
@nan
1999 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Therapeutic intervention with complement and beta-glucan in cancer.
@ast
Therapeutic intervention with complement and beta-glucan in cancer.
@en
type
label
Therapeutic intervention with complement and beta-glucan in cancer.
@ast
Therapeutic intervention with complement and beta-glucan in cancer.
@en
prefLabel
Therapeutic intervention with complement and beta-glucan in cancer.
@ast
Therapeutic intervention with complement and beta-glucan in cancer.
@en
P2093
P1433
P1476
Therapeutic intervention with complement and beta-glucan in cancer.
@en
P2093
P356
10.1016/S0162-3109(99)00013-2
P577
1999-05-01T00:00:00Z